168 related articles for article (PubMed ID: 18437019)
1. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis.
Park SJ; Han CW
J Korean Med Sci; 2008 Apr; 23(2):320-3. PubMed ID: 18437019
[TBL] [Abstract][Full Text] [Related]
2. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.
Cooray SD; Heerasing NM; Selkrig LA; Subramaniam VN; Hamblin PS; McDonald CJ; McLean CA; McNamara E; Leet AS; Roberts SK
J Med Case Rep; 2018 Jan; 12(1):18. PubMed ID: 29373985
[TBL] [Abstract][Full Text] [Related]
3. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
[No Abstract] [Full Text] [Related]
4. Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Lee JA; Tchantchaleishvili V; Vidula H
Artif Organs; 2018 May; 42(5):575-576. PubMed ID: 29878536
[No Abstract] [Full Text] [Related]
5. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
Spraul CW; Schicketanz C; Lang GE
Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
[TBL] [Abstract][Full Text] [Related]
6. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
[TBL] [Abstract][Full Text] [Related]
7. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
[TBL] [Abstract][Full Text] [Related]
8. The treatment of secondary hemochromatosis.
Gattermann N
Dtsch Arztebl Int; 2009 Jul; 106(30):499-504, I. PubMed ID: 19727383
[TBL] [Abstract][Full Text] [Related]
9. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
Boturao-Neto E; Marcopito LF; Zago MA
Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
[TBL] [Abstract][Full Text] [Related]
10. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).
Fabio G; Minonzio F; Delbini P; Bianchi A; Cappellini MD
Blood; 2007 Jan; 109(1):362-4. PubMed ID: 16960153
[TBL] [Abstract][Full Text] [Related]
11. [Hematologic improvement with deferasirox following tandem antithymocyte globulin treatment in a transfusion-dependent patient with severe aplastic anemia].
Jomen W; Kuroda H; Yamada M; Matsuno T; Sato M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Iyama S; Miyanishi K; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2047-52. PubMed ID: 24305537
[TBL] [Abstract][Full Text] [Related]
12. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
[TBL] [Abstract][Full Text] [Related]
13. Type 3 hemochromatosis and beta-thalassemia trait.
Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
[TBL] [Abstract][Full Text] [Related]
14. [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
Cario H; Grosse R; Janssen G; Jarisch A; Meerpohl J; Strauss G;
Klin Padiatr; 2010 Nov; 222(6):399-406. PubMed ID: 20862634
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
16. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
17. DIFFERENTIAL FERRIOXAMINE TEST FOR MEASURING CHELATABLE BODY IRON.
FIELDING J
J Clin Pathol; 1965 Jan; 18(1):88-97. PubMed ID: 14247711
[TBL] [Abstract][Full Text] [Related]
18. Current status of iron chelation therapy with deferoxamine.
Cohen A
Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation for iron overload secondary to transfusions of packed red blood cells.
Cid J
Clin Adv Hematol Oncol; 2014 Mar; 12(3):184-5. PubMed ID: 24927267
[No Abstract] [Full Text] [Related]
20. Hypoplastic anemia in cartilage-hair hypoplasia-balancing between iron overload and chelation.
Taskinen M; Toiviainen-Salo S; Lohi J; Vuolukka P; Gräsbeck M; Mäkitie O
J Pediatr; 2013 Apr; 162(4):844-9. PubMed ID: 23140882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
